908 Devices (MASS) Stock Price, News & Analysis

Company Overview

908 Devices Inc (NASDAQ: MASS) is a developer and manufacturer of portable analytical instruments designed to deliver rapid chemical detection in field and laboratory environments. The company’s core focus lies in miniaturizing high-performance mass spectrometry and ion mobility spectrometry technologies, enabling users to perform on-site analysis that traditionally required benchtop equipment.

Key products in 908 Devices’ portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations. These platforms are designed to offer fast sample-to-answer workflows with integrated data analysis software.

Founded in 2004 and headquartered in Boston, Massachusetts, 908 Devices leverages its proprietary micro-engineering and analytical expertise to serve customers around the world. The company’s instruments are employed across North America, Europe, Asia and other regions through a combination of direct sales, channel partners and strategic alliances.

The company’s solutions support a variety of applications, including security and defense screening, forensic investigations, environmental monitoring, pharmaceutical quality control and food safety testing. By providing real-time chemical intelligence at the point of need, 908 Devices aims to enhance operational efficiency and safety for government agencies, research institutions and commercial laboratories.

Key Stats

• Today's Range: $5.37 to $5.67
• 50-Day Range: $5.44 to $7.42
• 52-Week Range: $1.81 to $8.06
• Volume: 238,473 shs
• Average Volume: 236,374 shs
• Market Capitalization: $195.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Buy

908 Devices Stock Analysis - MarketRank™

908 Devices scored higher than 71% of companies evaluated by MarketBeat, and ranked 292nd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Buy

Consensus Rating

908 Devices has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

908 Devices has a consensus price target of $8.00, representing about 47.1% upside from its current price of $5.44.

Amount of Analyst Coverage

908 Devices has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for 908 Devices are expected to grow in the coming year, from ($1.99) to ($1.28) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of 908 Devices is -10.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 908 Devices is -10.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

908 Devices has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.61% of the float of 908 Devices has been sold short.

Short Interest Ratio / Days to Cover

908 Devices has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in 908 Devices has recently decreased by 0.99%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

908 Devices does not currently pay a dividend.

Dividend Growth

908 Devices does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.61% of the float of 908 Devices has been sold short.

Short Interest Ratio / Days to Cover

908 Devices has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in 908 Devices has recently decreased by 0.99%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.11

News Sentiment

908 Devices has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for 908 Devices this week, compared to 3 articles on an average week.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, 908 Devices insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $184,755.00 in company stock.

Percentage Held by Insiders

23.70% of the stock of 908 Devices is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.06% of the stock of 908 Devices is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MASS Stock Analysis - Frequently Asked Questions

How have MASS shares performed this year?

908 Devices' stock was trading at $2.20 at the beginning of the year. Since then, MASS shares have increased by 147.3% and is now trading at $5.44.

How were 908 Devices' earnings last quarter?

908 Devices Inc. (NASDAQ:MASS) announced its earnings results on Tuesday, August, 5th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.16) by $0.02. The firm earned $4.70 million during the quarter, compared to analyst estimates of $12.17 million. 908 Devices had a negative net margin of 30.54% and a negative trailing twelve-month return on equity of 24.30%.
Read the conference call transcript.

When did 908 Devices IPO?

908 Devices (MASS) raised $101 million in an initial public offering on Friday, December 18th 2020. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Cowen, SVB Leerink, Stifel and William Blair served as the underwriters for the IPO.

Who are 908 Devices' major shareholders?

908 Devices' top institutional investors include ARK Investment Management LLC (7.39%), GM Advisory Group LLC (3.25%), First Light Asset Management LLC (2.98%) and Geode Capital Management LLC (1.84%). Insiders that own company stock include Christopher D Brown, Kevin J Knopp, Joseph H Iv Griffith, Mark Spoto and Michael S Turner.
View institutional ownership trends.

How do I buy shares of 908 Devices?

Shares of MASS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of 908 Devices own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 908 Devices investors own include Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Visa (V).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 9/06/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:MASS
• CIK: 1555279
• Web: www.908devices.com
• Phone: 857-254-1500
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for 908 Devices: $8.00
• High Price Target: $12.00
• Low Price Target: $6.00
• Potential Upside/Downside: +47.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$72.21 million
• Net Margins: -30.54%
• Pretax Margin: -135.24%
• Return on Equity: -24.30%
• Return on Assets: -18.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.98
• Quick Ratio: 4.46

Sales & Book Value

• Annual Sales: $59.63 million
• Price / Sales: 3.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.29 per share
• Price / Book: 1.65

Miscellaneous

• Outstanding Shares: 35,860,000
• Free Float: 27,362,000
• Market Cap: $195.08 million
• Optionable: Optionable
• Beta: 0.37